KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Dividends Paid - Common (2019 - 2025)

Historic Dividends Paid - Common for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $34.3 million.

  • Royalty Pharma's Dividends Paid - Common rose 1051.97% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.2 million, marking a year-over-year increase of 3381.3%. This contributed to the annual value of $125.2 million for FY2024, which is 470.58% up from last year.
  • Latest data reveals that Royalty Pharma reported Dividends Paid - Common of $34.3 million as of Q3 2025, which was up 1051.97% from $38.6 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Dividends Paid - Common registered a high of $125.7 million during Q1 2021, and its lowest value of -$230.2 million during Q4 2021.
  • Its 5-year average for Dividends Paid - Common is $34.2 million, with a median of $33.4 million in 2023.
  • Over the last 5 years, Royalty Pharma's Dividends Paid - Common had its largest YoY gain of 11440.15% in 2022, and its largest YoY loss of 7254.64% in 2022.
  • Royalty Pharma's Dividends Paid - Common (Quarter) stood at -$230.2 million in 2021, then skyrocketed by 114.4% to $33.2 million in 2022, then fell by 26.13% to $24.5 million in 2023, then increased by 28.42% to $31.4 million in 2024, then increased by 9.01% to $34.3 million in 2025.
  • Its Dividends Paid - Common was $34.3 million in Q3 2025, compared to $38.6 million in Q2 2025 and $53.8 million in Q1 2025.